

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

ELITE PHARMACEUTICALS INC /DE/

Form 8-K

February 14, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

February 9, 2007

-----  
Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS, INC.

-----  
(Exact name of registrant as specified in its charter)

Delaware	333-45241	22-3542636
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

-----  
(Address of principal executive offices)

(201) 750-2646

-----  
(Registrant's telephone number, including area code)

-----  
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01

ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 8-K

On February 9, 2007, the Registrant and Dr. Behl entered into an Amended and Restated Employment Agreement under which Dr. Behl's position was changed from Chief Scientific Officer to Head of Technical Affairs and who is to report to the Chief Executive Officer, the Chief Scientific Officer and any additional executive officer designated by the Board of Directors of the Registrant (the "Board"). In addition, the definition of "cause" has been amended to include a determination by the Board, in its sole discretion, that the employment of Dr. Behl should terminate, provided that such termination will be effective on the 30th day after the written notice to Dr. Behl of such determination.

ITEM 8.01 OTHER EVENTS

On February 14, 2007, the Registrant issued a press release announcing the appointment of Veerappan Subramanian as its acting Chief Scientific Officer. A copy of the press release is attached hereto as exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

- a) Not applicable.
- b) Not applicable.
- c) Exhibits

10.1 Amended and Restated Employment Agreement, dated February 9, 2007, between the Registrant and Charan Behl, Ph.D.

99.1. Press Release, dated February 14, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 14, 2007

ELITE PHARMACEUTICALS, INC.

By: \_\_\_\_\_ /s/ Bernard Berk

-----  
Name: Bernard Berk  
Title: Chief Executive Officer